FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma (TNXP – Research Report), with a price ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...

Investing.com -- Shares of Tonix Pharmaceuticals Holding Corp. ( Nasdaq: TNXP) surged 18% after the company announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 26.61%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicatin ...

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Tonix Pharmaceuticals (NASDAQ: TNXP) announced its fourth-quarter and full-year 2024 financial results, alongside key operational updates. The compan ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...